Aprogen Biologics Inc. (KRX:003060)
South Korea · Delayed Price · Currency is KRW 236.00
+1.00 (0.43%)
At close: Apr 8, 2026
Aprogen Biologics Revenue
In the year 2025, Aprogen Biologics had annual revenue of 73.23B KRW with 8.68% growth. Aprogen Biologics had revenue of 20.36B in the quarter ending December 31, 2025, a decrease of -7.64%.
Revenue
73.23B
Revenue Growth
+8.68%
P/S Ratio
0.64
Revenue / Employee
187.28M
Employees
391
Market Cap
46.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.23B | 5.85B | 8.68% |
| Dec 31, 2024 | 67.38B | -19.99B | -22.88% |
| Dec 31, 2023 | 87.36B | 22.17B | 34.01% |
| Dec 31, 2022 | 65.19B | 8.71B | 15.42% |
| Dec 31, 2021 | 56.48B | 3.16B | 5.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 657.61B |
| Ildong Holdings | 590.89B |
| HANDOK | 535.14B |
| Dongwha Pharm.Co.,Ltd | 496.39B |
| MYUNGMOON Pharm co.,Ltd | 195.25B |
| Kukje Pharma | 175.50B |
| CKD Bio | 159.93B |
| Yuyu Pharma | 140.88B |